Laura Cohen

Expanded Results from a Dedicated Guideline-Directed Medical Therapy Clinic ➡️ bit.ly/4gUajBW

Ready to go on day 2! #ACCCTR @ACCinTouch @pamelasdouglas @TYWangMD @ShashankSinhaMD @_WayneBatchelor @DrJMieres @MelvinEchols9 @MCoylewright @DrLaPrincess

At #THT2025, we're transforming clinical trial findings into real-world impact! Join us for a dynamic session exploring strategies to expand access & reach in #HF treatment. @akshaydesaimd @laurapco @GivertzMichael @mrchrtfaildoc @NirUrielMD @JenHoCardiology @mvaduganathan

Heart failure is costly. How does the cost breakdown by EF and can #SGLT2i 💊offset these costs? @JJheart_doc and I explore this in an editorial (🔗tinyurl.com/yvxxvmck) to an excellent paper led by @vkittipibul, @SJGreene_md and others. Kudos to the authors #HF #JACCHF

🔥Fresh Press 🔥 We propose a novel candidate therapy for HFpEF. doi.org/10.1002/ejhf.3… @HFpEF @LitwinSheldon @KSharmaMD @MkosiborodMD @MidAmericaHeart @saintlukeskc

@ACCinTouch #ACCCTR 2024-24 Clinical Trials Research cohort and faculty at Heart House! @pamelasdouglas @MelvinEchols9 @TYWangMD @_WayneBatchelor @DrLaPrincess @ShashankSinhaMD #thefaceofcardiology

"Your science is only as good as your implementation science" #cmgsays again ... Dr. Jim Januzzi ( @JJheart_doc ) and I talk about implementation science in general but some of the advances he and his team are making in the heart failure space in particular which were presented at the European Heart Failure Association.

@JJheart_doc @drbennisahmed Thank you for your support as my GDMT co-chair and mentor @JJheart_doc!

@safchat @JJheart_doc @AferditaMD @MGHHeartHealth @MassGeneralNews Thanks for coming @safchat! Enjoy the rest of your time in Lisbon!

Excellent #LBCT presentation by @laurapco on cardiac reverse remodeling following an accelerated GDMT uptitration program #TEAMHF! 🔑 findings 👇

#HeartFailure2024 With Dr Laure Cohen ( TEAM-HF) and Dr @Manelcardio @JJheart_doc

#HeartFailure2024 Cardiac reverse remodeling in the trial of accelerated guideline-directed medical therapy for Heart Failure (TEAM-HF) Amazing

#HeartFailure2024 Together we are STRONGer. Efficacy of a multidisciplinary approach for fast up titration in patients with #HF. The TEAM-HF. #HFA_ESC @AferditaMD

Even so, it's important to at least try SGLT2 inhibitors in HFpEF patients who are good candidates, @laurapco says. "These are the only drugs that have shown a proven benefit in RCTs in improving CV outcomes" in this population @TCTMD @kardiologykazi tctmd.com/news/borderlin…

@LeonardChiuMD @katieptr @NealDixit @mvaduganathan @boback @ACCinTouch @laurapco @kardiologykazi Provides a cost-effectiveness/value perspective to these 💊💊💊 individually and in combination in HFpEF Class 2 (a/b) recommendations in HF guidelines SGLT2i+MRA+ARNI combo ➡️ intermediate value

@LeonardChiuMD @ACCinTouch @JAMACardio @kardiologykazi @gcfmd @NicolasIsazaMD @JenHoCardiology @HanCardiomd @ValleAlfonso Thank you @LeonardChiuMD, great to see you and meet your twin. 🎉 👏 on your excellent presentation!

Awesome presentation by @laurapco @ACCinTouch on Cost-effectiveness of SGLT2is in HFpEF, simultaneously published @JAMACardio. At current $, SGLT2i low to intermediate value for HFpEF Congrats! @kardiologykazi @gcfmd @NicolasIsazaMD @JenHoCardiology #ACC23 #CardioTwitter

@djc795 @JAMACardiology @kardiologykazi @GLewisCardiol @JenHoCardiology @gcfmd Thank you @djc795! I appreciate the thoughtful editorial with @ATSandhu

@laurapco @JAMACardiology @kardiologykazi @GLewisCardiol @JenHoCardiology @gcfmd Congratulations on an informative study and highly transparent reporting! Your paper was an absolute pleasure to read.

Honored to work with this amazing group on the cost-effectiveness of SGLT2is in HFpEF, published today @JAMACardiology and presented at #ACC23. We found SGLT2is are intermediate or low value for US adults with HFpEF (ICER $141,200/QALY).

@ersied727 Thank you @ersied727!

Results of economic evaluation suggest that at 2022 drug prices, adding an SGLT2-I to standard of care was of intermediate or low economic value compared with standard of care in US adults with HFpEF. ja.ma/41KDMWI #ACC23 #WCCardio @ihdezdelso

The ICER was most sensitive to changes in the hazard ratio for cardiovascular mortality and the drug price. While we can't change the ultimate answer regarding CV mortality in this population, lowering drug costs will lead to higher value.